Open-to-Accrual Therapeutic Trials


Breast Cancer

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

A011106
ClinicalTrials.gov #
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study S. Ghamande Sandra Wall Breast
III
A011202
ClinicalTrials.gov #
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy S. Ghamande
Sandra
Wall
Breast III 

GSK-201973  ClinicalTrials.gov #  NCT02964507

A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Fulvestrant in Subjects with ER+ Breast Cancer H. Boppidi Sandra Wall Breast I/II
INO-VT-464-CL-006
ClinicalTrials.gov #
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer   H. Boppidi
Sandra Wall Breast I / II 
ONT-380-206
ClinicalTrials.gov #
Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

  H. Boppidi

Sandra Wall Breast

II

NRG-BR003
ClinicalTrials.gov #
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer  S. Ghamande
Sandra
Wall
Breast III
NSABP-B55
ClinicalTrials.gov #

 

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy  S. Ghamande
Sandra
Wall
Breast III
S1207
ClinicalTrials.gov #
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer  S. Ghamande
Sandra
Wall
Breast III

S1416      ClinicalTrials.gov #  NCT02595905

 

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer S. Ghamande Sandra Wall Breast  II

S1418  ClinicalTrials.gov#  NCT02954874

A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy S. Ghamande Sandra Wall Breast  III